Literature DB >> 12325121

Cancer spread and micrometastasis development: quantitative approaches for in vivo models.

Ian C MacDonald1, Alan C Groom, Ann F Chambers.   

Abstract

Death from cancer is usually due to metastasis. Fortunately, most cells that escape from a primary tumor fail to form metastases. Identifying reasons for this failure will help development of anti-metastatic therapies. Intravital videomicroscopy (IVVM) can be used to observe cancer cells injected into live animals. Co-injected microspheres can be used to assess cell survival. These techniques have been used to show that circulating tumor cells generally arrest in the microcirculation and may extravasate with high efficiency. While many tumor cells may survive in a secondary site, only a small subset form micrometastases and only a subset of these micrometastases persist to form vascularized macrometastases. Furthermore, solitary tumor cells may remain dormant for long periods of time in secondary sites. These findings suggest that metastatic growth and angiogenesis are prime targets for anti-metastatic therapy. Copyright 2002 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12325121     DOI: 10.1002/bies.10156

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  52 in total

Review 1.  The two faces of transforming growth factor beta in carcinogenesis.

Authors:  Anita B Roberts; Lalage M Wakefield
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-14       Impact factor: 11.205

2.  Nanostructured Surfaces to Target and Kill Circulating Tumor Cells While Repelling Leukocytes.

Authors:  Michael J Mitchell; Carlos A Castellanos; Michael R King
Journal:  J Nanomater       Date:  2012       Impact factor: 2.986

3.  GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.

Authors:  Lei Xu; Shahinoor Begum; Jeremy D Hearn; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

Review 4.  Gastrointestinal cancer metastasis and lymphatic advancement.

Authors:  Kazuhide Kumagai; Kouji Shimizu; Noboru Yokoyama; Sadatsugu Aida; Takayuki Tanaka; Kennichi Yamagata
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

Review 5.  Optimising islet engraftment is critical for successful clinical islet transplantation.

Authors:  O Korsgren; T Lundgren; M Felldin; A Foss; B Isaksson; J Permert; N H Persson; E Rafael; M Rydén; K Salmela; A Tibell; G Tufveson; B Nilsson
Journal:  Diabetologia       Date:  2007-11-27       Impact factor: 10.122

Review 6.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Authors:  Megumi Iiizumi; Wen Liu; Sudha K Pai; Eiji Furuta; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2008-07-22

7.  Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs.

Authors:  Qing Chen; Xiang H-F Zhang; Joan Massagué
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

8.  Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.

Authors:  Alison L Allan; Rosamma George; Sharon A Vantyghem; Mark W Lee; Nicole C Hodgson; C Jay Engel; Ron L Holliday; David P Girvan; Leslie A Scott; Carl O Postenka; Waleed Al-Katib; Larry W Stitt; Toshimitsu Uede; Ann F Chambers; Alan B Tuck
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

9.  The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice.

Authors:  Ryang Hwa Lee; Min Jeong Seo; Andrey A Pulin; Carl A Gregory; Joni Ylostalo; Darwin J Prockop
Journal:  Blood       Date:  2008-09-25       Impact factor: 22.113

Review 10.  Local control by radiotherapy: is that all there is?

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  Breast Cancer Res       Date:  2008-11-05       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.